|
Members of the Duravest medical advisory board (MAB) are leading clinician-scientists who are world-renowned experts in their respective fields. In addition, they are also truly broad thinkers which is essential for the fundamentally interdisciplinary nature of convergent/combination medical technologies. The MAB (along with the scientific advisory board and other company advisors) is involved in the sourcing, evaluation and development of our subsidiary companies. Through their strong connections to the academic and scientific community, they are well-placed to bring outstanding scientific ideas to the attention of the Duravest team. The MAB is also involved in the evaluation of these opportunities as part of a comprehensive due-diligence program.
Of great importance is the involvement of the MAB in facilitating and accelerating the development of the Duravest subsidiaries. Their expertise in clinical trial development, outcomes research, physician adoption dynamics and other areas are crucial to the optimal and rapid development of medical technologies.
Peter Bonis, MD Articles by Dr. Bonis
Director of Research and Deputy Editor of Gastroenterology
UpToDate, Inc.
Assistant Professor of Medicine
Tufts University School of Medicine
Assistant Director
Tufts - NEMC Evidence Based Practice Center
Donald Landry, PhD MD Articles by Dr. Landry
Professor of Medicine
Columbia University College of Physicians & Surgeons
Director, Division of Experimental Therapeutics
Columbia University College of Physicians & Surgeons
John Lopez, MD Articles by Dr. Lopez
Director, Cardiac Catheterization and Interventional Cardiology
University of Chicago Hospitals
Associate Professor of Medicine
University of Chicago
Mehmet Oz, MD MBA Articles by Dr. Oz
Professor of Surgery
Columbia University College of Physicians & Surgeons
Director of the Cardiovascular Institute
Columbia-Presbyterian Medical Center
|
